Biochemical Testing After Pheochromocytoma Removal: How Early?

Abstract

Pheochromocytomas are catecholamine-producing tumors with typical clinical presentation. Tumor resection is considered as an appropriate treatment strategy. Due to its unpredictable clinical behavior, biochemical testing is mandatory to confirm the success of tumor removal after surgery. The aim of the study was to investigate the feasibility of a shorter interval of postoperative testing (earlier than the recommended 2–4 weeks according to recently published Guidelines). We investigated 81 patients with pheochromocytoma before and after surgery. Postoperative examination was performed of stable subjects after their transport from the surgical to the internal ward (7.1±2.2 days after surgery). Plasma metanephrines were used for the diagnosis of pheochromocytoma and confirmation of successful tumor removal. All subjects with pheochromocytoma had markedly elevated plasma metanephrines before surgery. No correlation between postoperative interval (the shortest being 3 days) and plasma metanephrine levels was found. Postoperative plasma metanephrine levels did not differ significantly from those taken at the one-year follow-up. In conclusion, we have shown that early postoperative diagnostic workup of subjects with pheochromocytoma is possible and may thus simplify early postoperative management of this clinical condition.

Key words

pheochromocytoma - paraganglioma - metanephrines - surgery

• References

• 1 Zelinka T, Eisenhofer G, Pacák K. Pheochromocytoma as a catecholamine producing tumor: implications for clinical practice. Stress 2007; 10: 195-203
• 2 Zelinka T, Petrák O, Turková H, Holaj R, Štrauch B, Kršek M, Brabcová-Vránková A, Musil Z, Dušková J, Kubinyi J, Michalský D, Novák K, Widimský Jr J. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res 2012; 44: 379-384
• 3 Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Mortality associated with phaeochromocytoma. Horm Metab Res 2013; 45: 154-158
• 4 Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069-4079
• 5 Mannelli M, Dralle H, Lenders JW. Perioperative management of pheochromocytoma/paraganglioma: is there a state of the art?. Horm Metab Res 2012; 44: 373-378
• 6 Lenders JW, Duh QY, Eisenhofer G, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young Jr WF. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 1915-1942
• 7 Bravo EL, Tarazi RC, Gifford RW, Stewart BH. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 1979; 301: 682-686
• 8 Eisenhofer G, Peitzsch M. Laboratory Evaluation of Pheochromocytoma and Paraganglioma. Clin Chem 2014; 60: 1486-1499
• 9 Petrák O, Haluzíková D, Kaválková P, Štrauch B, Rosa J, Holaj R, Brabcová Vránková A, Michalský D, Haluzík M, Zelinka T, Widimský Jr J. Changes in Energy Metabolism in Pheochromocytoma. J Clin Endocrinol Metab 2013; 98: 1651-1658
• 10 Amar L, Fassnacht M, Gimenez-Roqueplo AP, Januszewicz A, Prejbisz A, Timmers H, Plouin PF. Long-term postoperative follow-up in patients with apparently benign pheochromocytoma and paraganglioma. Horm Metab Res 2012; 44: 385-389
• 11 Lim V, Guo Q, Grant CS, Thompson B, Richards ML, Farley DR, Young Jr WF. Accuracy of adrenal imaging and adrenal venous sampling in predicting surgical cure of primary aldosteronism. J Clin Endocrinol Metab 2014; 99: 2712-2719
• 12 Amar L, Eisenhofer G. Clinical Question: Diagnosing phaeochromocytoma/paraganglioma in a patient presenting with critical illness: biochemistry versus imaging. Clin Endocrinol (Oxf) 2015; DOI: 10.1111/cen.12745. n/a-n/a
• 13 Eisenhofer G, Kopin IJ, Goldstein DS. Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004; 56: 331-349
• 14 Tsirlin A, Oo Y, Sharma R, Kansara A, Gliwa A, Banerji MA. Pheochromocytoma: a review. Maturitas 2014; 77: 229-238
• 15 Galati SJ, Said M, Gospin R, Babic N, Brown K, Geer EB, Kostakoglu L, Krakoff LR, Leibowitz AB, Mehta L, Muller S, Owen RP, Pertsemlidis DS, Wilck E, Xiao GQ, Levine AC, Inabnet WB. The Mount Sinai Clinical Pathway for the Management of Pheochromocytoma. Endocr Pract 2015; 21: 368-382
• 16 Plouin P-F, Amar L, Lepoutre C. Phaeochromocytomas and functional paragangliomas: Clinical management. Best Pract Res Clin Endocrinol Metab 2010; 24: 933-941
• 17 Lee JA, Duh QY. Sporadic paraganglioma. World J Surg 2008; 32: 683-687
• 18 Darr R, Lenders JW, Hofbauer LC, Naumann B, Bornstein SR, Eisenhofer G. Pheochromocytoma – update on disease management. Ther Adv Endocrinol Metab 2012; 3: 11-26
• 19 Osinga TE, van den Eijnden MH, Kema IP, Kerstens MN, Dullaart RP, de Jong WH, Sluiter WJ, Links TP, van der Horst-Schrivers AN. Unilateral and Bilateral Adrenalectomy for Pheochromocytoma Requires Adjustment of Urinary and Plasma Metanephrine Reference Ranges. J Clin Endocrinol Metab 2013; 98: 1076-1083